Akero Therapeutics Inc (NASDAQ:AKRO) has coverage initiated with a Outperform ➝ Outperform rating and $35.00 price target

Analyst Ratings For Akero Therapeutics Inc (NASDAQ:AKRO)

Story continues below

Today, Evercore ISI initiated coverage on Akero Therapeutics Inc (NASDAQ:AKRO) with a Outperform with a price target of $35.00.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Akero Therapeutics Inc (NASDAQ:AKRO) is Buy with a consensus target price of $31.25 per share, a potential 53.75% upside.

Some recent analyst ratings include

  • 7/15/2019-Akero Therapeutics Inc (NASDAQ:AKRO) has coverage initiated with a Outperform ➝ Outperform rating and $35.00 price target
  • 7/15/2019-Akero Therapeutics Inc (NASDAQ:AKRO) has coverage initiated with a Buy ➝ Buy rating and $28.00 price target
  • 7/15/2019-Akero Therapeutics Inc (NASDAQ:AKRO) has coverage initiated with a Buy ➝ Buy rating and $34.00 price target
  • 7/15/2019-Akero Therapeutics Inc (NASDAQ:AKRO) has coverage initiated with a Overweight ➝ Overweight rating and $28.00 price target

    Recent Trading Activity for Akero Therapeutics Inc (NASDAQ:AKRO)
    Shares of Akero Therapeutics Inc closed the previous trading session at 20.33 up +0.45 2.26% with 19.83 shares trading hands.

    An ad to help with our costs